Authors
Latest:
Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter ValidationRapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.
Latest:
Dr. Bastholt on Lenvatinib in Thyroid CancerLars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses lenvatinib (Lenvima) in patients with thyroid cancer.
Latest:
A Life Redirected: Pursuing a Nursing Career After OsteosarcomaIn the summer of 2010, 20-year-old physical therapy student Hannah Komai was diagnosed with low-grade osteosarcoma after an incisional biopsy.
Latest:
Dr. Michaelis on Safety Considerations With Venetoclax/Azacitidine in AMLLaura C. Michaelis, MD, discusses safety considerations with the combination of venetoclax and azacitidine in acute myeloid leukemia.
Latest:
Dr Dawson on Palliative Radiotherapy in Symptomatic HCC or Liver MetastasesLaura Dawson, MD, FRCPC, discusses the investigation of palliative radiotherapy for patients with symptomatic hepatocellular carcinoma or liver metastases.
Latest:
Dr. Esserman on Screening Patients With Higher-Risk DCISLaura Esserman, MD, MBA, Professor, University of California, San Francisco, discusses screening patients with higher-risk DCIS.
Latest:
Dr. Esserman on Personalized Screenings for Breast CancerLaura Esserman, MD, MBA, professor, University of California, San Francisco, discusses personalized versus annual screenings for breast cancer.
Latest:
Dr. Esserman Discusses the I-SPY 2 TrialLaura J. Esserman, MD, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.
Latest:
Dr. Esserman on the I-SPY2 Trial in Breast CancerLaura J. Esserman, MD, MBA, discusses the rationale and design for the phase 2 I-SPY2 trial.
Latest:
Dr. Holman on Screening for Ovarian CancerLaura L. Holman, MD, discusses screening options for ovarian cancer.
Latest:
Dr. Freedman on the NCCN Guidelines for Post-Mastectomy RadiationLaura M. Freedman, MD, assistant professor, director of Radiation Oncology, Sylvester Comprehensive Cancer Center, discusses the revised National Comprehensive Cancer Network (NCCN) guidelines for post-mastectomy radiation given in women who have pathologic T1 and T2 tumors and 1 to 3 positive lymph nodes.
Latest:
Informed Patients Are More Likely to Choose Palliative CareResearch from Tulane University provides a strong case that, across demographic and clinical populations, informed patients are less wary of palliative care and more inclined to take advantage of the favorable effects that palliative care services can offer for patient-centered outcomes.
Latest:
Laura Metcalfe on Colorectal ScreeningLaura Metcalfe, MSN, RN, APN, C, AOCNS Advanced Practice Nurse, GI Division from John Theurer Cancer Center on Colorectal Screening
Latest:
Dr. Michaelis Discusses the JAK2 Mutation in MPNsLaura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses implications for the JAK2 mutation in patients with myeloproliferative neoplasms.
Latest:
Expert Discusses Promise of Quizartinib in AMLMark Levis, MD, PhD, highlights the promise and potential challenges of the FLT3-inhibitor quizartinib in acute myeloid leukemia.
Latest:
Dr. Chow on the Use of Ceritinib in ALK+ NSCLC Metastatic to the BrainLaura Quan Man Chow, MD, FRCPC, discusses the use of ceritinib (Zykadia) in patients with ALK-positive non–small cell lung cancer that has metastasized to the brain.
Latest:
Exciting Data in the Treatment of HER2-low from SABCS 2023Laura Spring, MD, and Manali Bhave, MD, highlight promising new systemic treatment options on the horizon for patients with metastatic breast cancer, including T-DM1 for HER2-low disease, the AKT inhibitor capivasertib, and novel endocrine therapies.
Latest:
Dr. van 't Veer on Guidelines for Genetic Testing in Breast CancerLaura van ’t Veer, PhD, Leader of the Breast Oncology Program, and director of Applied Genomics, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the guidelines for genetic testing in breast cancer.
Latest:
The Evolving Treatment Landscape of Biliary Tract CancersClosing out their discussion on biliary tract cancers, Milind Javle, MD, and Laura Goff, MD, highlight current treatment guidelines and unmet needs as the landscape continues to evolve.
Latest:
Denosumab: A Review of Its Pharmacology and Clinical ImplicationsIt is estimated that approximately 80% of all patients with diagnoses of breast cancer, prostate cancer, or multiple myeloma will develop bone metastases at some time during the course of their disease.
Latest:
Challenging Case Teaches Oncology Fellow the Power of HopeAdvanced esophageal cancer is a highly lethal malignancy and often spreads despite aggressive therapy.
Latest:
Dr. Rice on the Importance of Clinical Trials in Gynecologic CancerLaurel W. Rice, MD, chair, Department of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, discusses the importance of enrolling patients with gynecologic cancer on clinical trials.
Latest:
New Perioperative Strategies Emerge for High-Risk, Resectable RCCThe current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.
Latest:
The Therapeutic Landscape of Metastatic Renal Cell Carcinoma in 2012In the last seven years, since the introduction of the targeted therapies, remarkable progress has transpired that has transformed the therapeutic landscape for metastatic renal cell carcinoma.
Latest:
Dr. Carcas on the Design and Findings of CONTROL Trial in HER2+ Breast CancerLauren Carcas, MD, medical oncologist, Miami Cancer Institute, Baptist Health South Florida, discusses the design of the CONTROL trial and her personal experience with prophylaxis interventions for women with early-stage HER2-positive breast cancer receiving neratinib (Nerlynx).
